Simon Charles Goodacre

This inventor holds 15 USPTO granted patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2003-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simon Charles Goodacre. Retrieved from https://idiyas.com/inventor/simon-charles-goodacre-vx02z0mt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 6.7

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 124(Granted Patents)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

patents

Years Active: 2003-2009

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7485640 - Imidazopyrazinones as GABA-A receptor anxiolytics (2009-02-03),

2. 7279580 - Imidazo-pyridine derivatives as ligands for GABA receptors (2007-10-09),

3. 7226926 - 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors (2007-06-05),

4. 7176203 - Imidazo-triazine derivatives as ligands for gaba receptors (2007-02-13),

5. 7148222 - [object Object] (2006-12-12),

6. 7030128 - Imidazo-pyrimidine derivatives as ligands for GABA receptors (2006-04-18),

7. 7005431 - Imidazo-triazine derivatives as ligands for gaba receptors (2006-02-28),

8. 6969716 - 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression (2005-11-29),

9. 6914063 - Imidazo-pyrazine derivatives as ligands for GABA receptors (2005-07-05),

10. 6914060 - Imidazotriazinone derivatives as ligands for GABA receptors (2005-07-05),

11. 6900215 - Imidazo-pyrimidine derivatives as ligands for gaba receptors (2005-05-31),

12. 6887885 - Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands (2005-05-03),

13. 6872731 - Imidazo-pyridine derivatives as ligands for GABA receptors (2005-03-29),

14. 6730681 - Triazolo-pyrimidine derivatives as ligands for gaba receptors (2004-05-04),

15. 6642229 - 3-Phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors (2003-11-04),

Title: The Innovative Mind of Simon Charles Goodacre

Introduction: Simon Charles Goodacre, an accomplished inventor based in Benington, GB, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 15 patents. His innovative work primarily focuses on compounds that target GABA receptors, which play a crucial role in the treatment of central nervous system disorders such as anxiety and cognitive impairments.

Latest Patents: Goodacre’s recent inventions include "Imidazopyrazinones as GABA-A receptor anxiolytics," which details a novel class of compounds designed for the treatment and prevention of anxiety and cognitive disorders. This patent outlines a sophisticated chemical structure capable of impacting the central nervous system effectively. Additionally, he developed "Imidazo-pyridine derivatives as ligands for GABA receptors," which describes selective ligands aimed at enhancing GABA receptor activity, particularly beneficial for conditions related to anxiety, convulsions, and cognitive difficulties.

Career Highlights: Goodacre currently operates within the esteemed Merck Sharp & Dohme Corporation, where he focuses on advancing pharmaceutical innovation. His work is significant in the realm of neuropharmacology, contributing to safer and more effective treatments for patients suffering from various CNS disorders.

Collaborations: Throughout his career, Goodacre has collaborated with notable peers such as David James Hallett and Leslie Joseph Street. These collaborations have undoubtedly enriched his research and contributed to the success of his patented inventions, reinforcing the importance of teamwork in the field of scientific innovation.

Conclusion: Simon Charles Goodacre stands out as a prominent figure in the realm of pharmaceutical invention, with a specific focus on compounds that enhance GABA receptor function. His portfolio of patents, combined with his strategic collaborations and role at Merck Sharp & Dohme Corporation, highlight his dedication to pushing the boundaries of medical science. He continues to inspire future innovations and contribute to the betterment of mental health treatments.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]